REG - Iconic Labs PLC - Issue of Equity

Iconic LabsAnnouncement

16/08/2019 14:50

RNS Number : 3831J
Iconic Labs PLC
16 August 2019
 


16 August 2019
Iconic Labs Plc ("Iconic Labs" or the "Company")
 
Issue of Equity
 
Iconic Labs Plc (LSE:ICON), a multi-divisional new media and technology business, announces that further to the RNS dated 6 August 2019, the Company has issued 237,827,207 Ordinary Shares ("the Ordinary Shares") to European High Growth Opportunities Securitization Fund and application has been made to the London Stock Exchange for the Ordinary Shares to be admitted to trading on the Main Market of the LSE.
 
It is expected that admission will become effective and dealings in the Ordinary Shares will commence on or around 20 August 2019. The Ordinary Shares shall rank pari passu with the existing Ordinary Shares in the Company. 
 
Following admission of the 237,827,207 Ordinary Shares, the Company's issued share capital will consist of 1,637,129,905 Ordinary Shares with voting rights and that figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
 
**ENDS**
 
For further information, please visit the Company's website www.iconiclabs.co.uk, email IR@iconiclabs.co.uk or contact:
 



John Quinlan


Iconic Labs Plc


c/o SBP Tel: +44 (0) 20 7236 1177




Damon Heath


Shard Capital Partners LLP


Tel: +44 (0) 20 7186 9950




Erik Woolgar


Shard Capital Partners LLP


Tel: +44 (0) 20 7186 9950




Melissa Hancock


St Brides Partners Limited


Tel: +44 (0) 20 7236 1177




Juliet Earl


St Brides Partners Limited


Tel: +44 (0) 20 7236 1177



 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEPFMJTMBIBBIL